The global next-generation antibody therapeutics market was valued at $1,490.0 million in 2014 and it is expected to grow at a CAGR of 20.9% during the period 2015 – 2020. The global next-generation antibody therapeutics market is increasing due to growing global R&D activities. Various pharmaceutical and biotechnology companies are engaged in R&D for new improved next-generation antibody therapeutics, which would help in improved treatment of various chronic diseases, such as cancer, diabetes, cardiovascular diseases, infectious diseases and others. In addition, various pharmaceutical and biotechnology companies are involved in collaborations with other companies and organizations for the research and development of next-generation antibody therapeutics. Technological advancements in the field of next-generation antibody therapeutics are also driving the market. Recombinant technology has facilitated development of new and improved antibody therapeutics. Antibodies are genetically engineered to create smaller fragments of antibodies in order to increase their penetration into cancer cells. Such advancements in technology have resulted in the improved treatment options; and thus, are gaining popularity.
Browse report description with detailed TOC on “Global Next-generation Antibody Therapeutics Market Size, Share, Development, Growth and Demand Forecast to 2020” at:
Based on therapeutic area, the autoimmune/inflammatory next-generation antibody therapeutics market is expected to witness the faster growth during the forecast period of 2015-2020. On the basis of technology, the next-generation antibody therapeutics market can be segmented as antibody-drug conjugates (ADCs), bispecific antibodies, Fc-engineered antibodies, antibody fragments and antibody-like proteins, and biosimilar antibody products. The biosimilar antibody products segment is expected to witness the fastest growth, CAGR of 22.5%, during the period 2015 – 2020.
The information and data in the publication “Global Next-generation Antibody Therapeutics Market Size, Share, Development, Growth and Demand Forecast to 2020” represent the research and analysis of data from various primary and secondary sources. Bottom-up approach has been used to calculate the global next-generation antibody therapeutics market by therapeutic area and technology. The market numbers for countries are obtained through top-down approach. P&S Market Research analysts and consultants interact with leading companies of the concerned domain to substantiate every single data presented in this report. We base our primary research on discussions with prominent professionals and analysts in the industry, aided by informed and detailed online and offline research.
Browse more reports on Healthcare:
Biosimilar antibody product refers to a copy of an already-authorized product, whose patent has expired. The cost of biosimilar antibody products being very low, as compared to the original antibody products, drives the demand of biosimilar antibody products market, specifically in low income regions and emerging markets of Asia-Pacific, Latin America, and Eastern Europe.
The increasing healthcare expenditure across the globe is encouraging consumers to use more number of next-generation antibody therapeutics to get improved treatment. Governments of various countries have been taking initiatives to provide improved healthcare facilities at affordable prices. In addition, another factor including growing prevalence of chronic diseases is driving the next-generation antibody therapeutics market at a significant rate. Next-generation antibody therapeutics provides improved treatment options for the treatment of chronic diseases, with minimum side effects.
However, certain restraints such as high cost of next-generation antibody therapeutics and strict regulatory requirements and long approval time for new drugs are hindering the market growth. Rural areas in the developing countries are emerging as a potential opportunity for the next-generation antibody therapeutics market.
The increasing healthcare expenditure and improving healthcare facilities in developing countries, such as China, India, and Brazil, are laying significant opportunity for next-generation antibody therapeutics market. North America next-generation antibody therapeutics market is expected to witness the fastest growth of CAGR 23.5% during the period 2015 – 2020. This is as a result of increasing number of chronic diseases cases, increasing healthcare expenditure, and rising R&D investments in the region. In addition, high adoption rate for improved healthcare facilities is boosting the market for next-generation antibody therapeutics market.
The key companies operating in the global next-generation antibody therapeutics market include Kyowa Hakko Kirin Co., Ltd., Dyax Corp., AstraZeneca plc, F.Hoffmann-La Roche Ltd, Bayer AG, Pfizer, Inc., Seattle Genetics, Inc., Bristol-Myers Squibb Company, Takeda Pharmaceuticals Company Limited, and Biogen.
NEXT-GENERATION ANTIBODY THERAPEUTICS MARKET SEGMENTATION
Next-Generation Antibody Therapeutics Market by Therapeutic Area
Next-Generation Antibody Therapeutics Market by Technology
- Antibody-drug conjugates (ADCs)
- Biosimilar antibody products
- Antibody fragments and antibody-like proteins
- Fc-engineered antibodies
- Bispecific antibodies
Next-Generation Antibody Therapeutics Market by Region
- North America
- The U.S.
- Rest of North America
- The U.K.
- Rest of Europe
- Rest of Asia-Pacific
- Rest of the World (ROW)
About P&S Market Research
P&S Market Research is a global market research and consulting company. We provide market research reports, industry reports, business intelligence and research based consulting services across a range of industries.
With the help of our professional corporate relations with various companies, our market research offers the most accurate market forecasting. Our analysts and consultants interact with leading companies of the concerned domain to substantiate every single data presented in our publication. Our research assists our client in identifying new and different windows of opportunity and frame informed and customized strategies for expansion in different regions.
Company Name: P&S Market Research
Contact Person: Ms Somya, Manager – Client Partner
Phone: +1-888-778-7886 (USA/Canada Toll-Free)
Address:347, 5th Ave. #1402
City: New York City
Country: United States